Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhiyi Bio to Start US Trial of Live Biotherapy for Chemotherapy-Induced Diarrhea

publication date: Oct 18, 2022

Guangzhou Zhiyi Biotech was approved to start US Phase I trial of its live biopharmaceutical product to treat chemotherapy-induced diarrhea (CID). SK10, an inactivated Bacteroides fragilis-based LBP, has shown efficacy in CID models, according to Zhiyi. It is the first LBP product approved for CID trials globally. Zhiyi says the US approval is a milestone for the company, starting trials of an LBP product in the US and China. Earlier this year, Zhiyi raised $15 million in its B++ funding, bringing the total of three B rounds to $45 million. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital